Medicines Aktie [WKN: 938858 / ISIN: US5846881051]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Medicines Co.

06.01.20		Novartis Completes Tender Offer For Medicines Co. (RTTNews)
05.12.19		Novartis Commences Tender Offer For Medicines Company (RTTNews)
26.11.19		Today's Top 5 Gainers In Healthcare Sector (SRNE, MDCO, RAPT...) (RTTNews)
25.11.19		Novartis To Buy Medicines Co. In $9.7 Bln Deal (RTTNews)
24.11.19		The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion (Businesswire)
19.11.19		KRTX Makes Giant Leap, The Medicines' Working Well, AGRX On The Move (RTTNews)
18.11.19		The Medicines Company Announces that the ORION-9 Study of Inclisiran in HeFH Patients Showed Durable and Potent LDL-C Lowering with Twice-Yearly Dosing (Businesswire)
16.11.19		The Medicines Company Announces that the ORION-10 Study of Inclisiran in ASCVD Patients Showed Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing (Businesswire)
06.11.19		The Medicines Company to Present Inclisiran Data from ORION-9 and ORION-10 Pivotal Phase 3 Clinical Studies at American Heart Association Scientific Sessions 2019 (Businesswire)
30.10.19		The Medicines Company Reports Third-Quarter 2019 Financial Results and Achievement of Major Milestones for Inclisiran (Businesswire)
24.10.19		The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30 (Businesswire)
17.10.19		Healthcare Stocks That Hit New Highs(MLSS, MDCO, CBPO...) (RTTNews)
04.10.19		The Medicines Company to Participate in the Chardan 3rd Annual Genetic Medicines Conference (Businesswire)
25.09.19		The Medicines Company Announces Positive Topline Results for ORION-10 Phase 3 Study of Inclisiran in ASCVD Patients (Businesswire)
25.09.19		The Medicines Company Announces Positive Topline Results for ORION-9 Phase 3 Study of Inclisiran in Heterozygous Familial Hypercholesterolemia Patients (Businesswire)
02.09.19		The Medicines Company Presents Results from ORION-11, First Phase 3 Trial of Inclisiran, Showing Durable and Potent Lowering of LDL-C with Twice-Yearly Dosing (Businesswire)
26.08.19		The Medicines Company Announces Positive Topline Results from First Pivotal Phase 3 Trial of Inclisiran (Businesswire)
24.07.19		The Medicines Company Reports Second-Quarter 2019 Financial Results and Updates Clinical Development Program (Businesswire)
17.07.19		The Medicines Company to Announce Second Quarter 2019 Financial Results on July 24 (Businesswire)
26.06.19		The Medicines Company Announces Pricing of Public Offering of Common Stock (Businesswire)
24.06.19		The Medicines Company Announces Launch of Public Offering of Common Stock (Businesswire)
27.05.19		The Medicines Company Presents Clinical Data Analyses for Inclisiran at 87th European Atherosclerosis Society Congress (Businesswire)
18.05.19		New Long-Term Data Show that Twice-a-Year Dosing with Inclisiran Results in Persistent Lowering of LDL Cholesterol with No Material Safety Observations Out to Three Years (Businesswire)
10.05.19		The Medicines Company to Host Investor Conference Call and Webcast During National Lipid Association’s 2019 Scientific Sessions (Businesswire)
25.04.19		The Medicines Company Reports First-Quarter 2019 Financial Results and Significant Progress with the Inclisiran Clinical Development Program (Businesswire)
18.04.19		The Medicines Company to Announce First Quarter 2019 Financial Results on April 25 (Businesswire)
21.02.19		The Medicines Company Announces Upcoming Investor Conference Presentations (Businesswire)
20.02.19		The Medicines Company to Announce Fourth-Quarter and Full-Year 2018 Financial Results on February 27 (Businesswire)
07.01.19		The Medicines Company Announces 5th Review of Un-blinded Data and Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase 3 Trials (Businesswire)
21.12.18		FDA Nod For GNMK, AKRX Gets New CEO, PTI Plunges After-hours (RTTNews)
14.12.18		The Medicines Company Prices $150 Million of Convertible Notes (Businesswire)
13.12.18		GLMD On Watch, ARDS On The Move, MDCO Gets New CEO (RTTNews)
11.12.18		The Medicines Company Appoints Mark Timney as Chief Executive Officer (Businesswire)
09.11.18		Company Profile for The Medicines Company (Businesswire)
08.11.18		The Medicines Company Reports Third-Quarter 2018 Results (Businesswire)
01.11.18		The Medicines Company to Announce Third-Quarter 2018 Financial Results on November 8 (Businesswire)
01.08.18		The Medicines Company Reports Second-Quarter 2018 Results (Businesswire)
26.07.18		The Medicines Company to Announce Second-Quarter 2018 Financial Results on August 1 (Businesswire)
27.06.18		The Medicines Company Announces Recommendation by Independent Data Monitoring Committee to Continue Inclisiran Phase III Trials Following [Third] Review of Unblinded Data (Businesswire)
26.06.18		New Data Presented at the American Diabetes Association 78th Scientific Sessions® Reinforce the Potential of The Medicines Company’s inclisiran in Patients with Diabetes (Businesswire)
07.05.18		The Medicines Company Announces Inclisiran Data Showing Significant Reductions in Potentially Harmful Subtypes of Bad Cholesterol (Atherogenic Lipoproteins) Linked to Heart Attack and Stroke (Businesswire)
30.04.18		The Medicines Company Presents New Data at the National Lipid Association Scientific Sessions (Businesswire)
25.04.18		The Medicines Company Reports First-Quarter 2018 Results (Businesswire)
19.04.18		The Medicines Company to Announce First-Quarter 2018 Financial Results on April 25 (Businesswire)
09.03.18		FDA Panel Backs Xeljanz For UC, ACRX Abuzz, AGLE Awaits Data This Month (RTTNews)
23.01.18		ARRY Shines A BEACON, So Long To JUNO And BIVV, Exciting Time Ahead For GEMP (RTTNews)
08.01.18		Sanofi And Alnylam Restructure RNAi Therapeutics Rare Disease Alliance (RTTNews)
29.11.17		Medicines Co. To Sell Infectious Disease Business Unit To Melinta Therapeutics (RTTNews)
29.11.17		Deerfield Supports Melinta Therapeutics Acquisition of The Medicines Company's Infectious Disease Business with a $240 million Commitment to Melinta and a $100 million Commitment to The Medicines... (PR Newswire)
06.11.17		Medicines Co., Alnylam Pharma Initiate Phase III Clinical Trial Of Inclisiran (RTTNews)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 17:40
Kaufwert:	EUR
	Hinzufügen Speichern